Role of efflux pumps and metabolising enzymes in drug delivery

Expert Opinion on Drug Delivery

Volumn 2, Issue 4, 2005, Pages 683-705

  Katragadda, Suresh ^c   Budda, Balasubrahmanyam ^c   Anand, Banmeet S ^b   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b GENENTECH INC   (United States)

^c NONE

Author keywords

ATP binding cassette; BCRP; Cmax; Cytochrome P450; MRPs; Multi drug resistance; P glycoprotein; Protease inhibitors; SSRIs

Indexed keywords

ABC TRANSPORTER; ACEBUTOLOL; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; DACTINOMYCIN; DEXAMETHASONE; DIGOXIN; DOXORUBICIN; DRUG METABOLIZING ENZYME; ETOPOSIDE; FEXOFENADINE; GLYCOPROTEIN P; INDINAVIR; KETOCONAZOLE; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; PACLITAXEL; PHENYTOIN; QUINIDINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE;

AREA UNDER THE CURVE; ATAXIA; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG TRANSPORT; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; INTESTINE ABSORPTION; MULTIPLE MYELOMA; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; GENE THERAPY; HUMANS; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PRODRUGS;

EID: 22844451077     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.4.683     Document Type: Review

References (242)

1. WACHER VJ, WU CY, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. (1995) 13(3):129-134.
2. HOLLAND IB, BLIGHT MA: ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. J. Mol. Biol. (1999) 293(2):381-399.
3. LEGARE D, RICHARD D, MUKHOPADHYAY R et al.: The leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. (2001) 276(28):26301-26307.
4. BAKOS E, HEGEDUS T, HOLLO Z et al.: Membrane topology and glycosylation of the human multidrug resistance-associated protein. J. Biol. Chem. (1996) 271(21):12322-12326.
5. HIPFNER DR, ALMQUIST KC, LESLIE EM et al.: Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. (1997) 272(38):23623-23630.
6. KAST C, GROS P: Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J. Biol. Chem. (1997) 272(42):26479-26487.
7. KAGE K, TSUKAHARA S, SUGIYAMA T et al.: Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer (2002) 97(5):626-630.
8. URBATSCH IL, SANKARAN B, BHAGAT S, SENIOR AE: Both P-glycoprotein nucleotide-binding sites are catalytically active. J. Biol. Chem. (1995) 270(45):26956-26961.
9. GOTTESMAN MM, AMBUDKAR SV: Overview: ABC transporters and human disease. J. Bioenerg. Biomembr. (2001) 33(6):453-458.
10. JULIANO RL, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. (1976) 455(1):152-162.
11. RAVIV Y, POLLARD HB, BRUGGEMANN EP, PASTAN I, GOTTESMAN MM: Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. (1990) 265(7):3975-3980.
12. AMBUDKAR SV, DEY S, HRYCYNA CA et al.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (1999) 39:361-398.
13. AUNGST BJ: P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. (1999) 39(1-3):105-116.
14. SUZUKI H, SUGIYAMA Y: Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. (2000) 12(1):3-12.
15. THIEBAUT F, TSURUO T, HAMADA H et al.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84(21):7735-7738.
16. CORDON-CARDO C, O'BRIEN JP, CASALS D et al.: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA (1989) 86(2):695-698.
17. SUGAWARA I, KATAOKA I, MORISHITA Y et al.: Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. (1988) 48(7):1926-1929.
18. LOO TW, CLARKE DM: Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. (2002) 277(46):44332-44338.
19. LOO TW, CLARKE DM: Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site. Proc. Natl. Acad. Sci. USA (2002) 99(6):3511-3516.
20. HIGGINS CF, GOTTESMAN MM: Is the multidrug transporter a flippase? Trends Biochem. Sci. (1992) 17(1):18-21.
21. EYTAN GD, KUCHEL PW: Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cytol. (1999) 190:175-250.
22. SHAROM FJ: The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. (1997) 160(3):161-175.
23. MARTIN C, BERRIDGE G, HIGGINS CF et al.: Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. (2000) 58(3):624-632.
24. DEY S, RAMACHANDRA M, PASTAN I, GOTTESMAN MM, AMBUDKAR SV: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. USA (1997) 94(20):10594-10599.
25. DIDZIAPETRIS R, JAPERTAS P, AVDEEF A, PETRAUSKAS A: Classification analysis of P-glycoprotein substrate specificity. J. Drug Target (2003) 11(7):391-406.
26. FAN K, FAN D, CHENG LF, LI C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. (2000) 20(6C):4809-4814.
27. CAMPOS L, GUYOTAT D, ARCHIMBAUD E et al.: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood (1992) 79(2):473-476.
28. CUMBER PM, JACOBS A, HOY T et al.: Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br. J. Haematol. (1990) 76(2):226-230.
29. VERRELLE P, MEISSONNIER F, FONCK Y et al.: Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. (1991) 83(2):111-116.
30. MARIE JP, ZHOU DC, GURBUXANI S, LEGRAND O, ZITTOUN R: MDR1/P-glycoprotein in haematological neoplasms. Eur. J. Cancer (1996) 32A(6):1034-1038.
31. FOJO AT, UEDA K, SLAMON DJ et al.: Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA (1987) 84(1):265-269.
32. FOJO AT, SHEN DW, MICKLEY LA, PASTAN I, GOTTESMAN MM: Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J. Clin. Oncol. (1987) 5(12):1922-1927.
33. FARDEL O, LECUREUR V, GUILLOUZO A: The P-glycoprotein multidrug transporter. Gen. Pharmacol. (1996) 27(8):1283-1291.
34. DE KANT E, HEIDE I, THIEDE C, HERRMANN R, ROCHLITZ CF: MDR1 expression correlates with mutant p53 expression in colorectal cancer metastases. J. Cancer Res. Clin. Oncol. (1996) 122(11):671-675.
35. HSU CH, CHEN CL, HONG RL et al.: Prognostic value of multidrug resistance 1, glutathione-S-transferase-pi and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology (2002) 62(4):305-312.
36. ISRAELI D, ZIAEI S, GONIN P, GARCIA L: A proposal for the physiological significance of mdr1 and Bcrp1/Abcg2 gene expression in normal tissue regeneration and after cancer therapy. J. Theor. Biol. (2005) 232(1):41-45.
37. HUNTER J, JEPSON MA, TSURUO T, SIMMONS NL, HIRST BH: Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. (1993) 268(20):14991-14997.
38. HUNTER J, HIRST BH, SIMMONS NL: Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. (1993) 10(5):743-749.
39. SPARREBOOM A, VAN ASPEREN J, MAYER U et al.: Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA (1997) 94(5):2031-2035.
40. KIM RB, FROMM MF, WANDEL C et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. (1998) 101(2):289-294.
41. TERAO T, HISANAGA E, SAI Y, TAMAI I, TSUJI A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J. Pharm. Pharmacol. (1996) 48(10):1083-1089.
42. RAMAKRISHNAN P: The role of P-glycoprotein in the blood-brain barrier. Einstein Quart. J. Biol. Med. (2003) 19:160-165.
43. VOGELGESANG S, WARZOK RW, CASCORBI I et al.: The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Current Alzheimer Research (2004) 1(2):121-125.
44. POTSCHKA H, LOSCHER W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia (2001) 42(10):1231-1240.
45. WACHER VJ, SILVERMAN JA, ZHANG Y, BENET LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. (1998) 87(11):1322-1330.
46. VAN ASPEREN J, VAN TELLINGEN O, SPARREBOOM A et al.: Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprorein blocker SDZ PSC 833. Br. J. Cancer (1997) 76(9):1181-1183.
47. GAN LS, MOSELEY MA, KHOSLA B et al.: CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos. (1996) 24(3):344-349.
48. RAEISSI SD, HIDALGO IJ, SEGURA-AGUILAR J, ARTURSSON P: Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm. Res. (1999) 16(5):625-632.
49. SU SF, HUANG JD: Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab. Dispos. (1996) 24(2):142-147.
50. KUSUHARA H, SUZUKI H, SUGIYAMA Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. (1998) 87(9):1025-1040.
51. LYUBIMOV E, LAN LB, PASHINSKY I, STEIN WD: Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anticancer Drugs (1996) 7(1):60-69.
52. GONZALEZ O, COLOMBO T, DE FUSCO M et al.: Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother. Pharmacol. (1995) 36(4):335-340.
53. SCHUETZ EG, SCHINKEL AH, RELLING MV, SCHUETZ JD: P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. USA (1996) 93(9):4001-4005.
54. HORI R, OKAMURA N, AIBA T, TANIGAWARA Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J. Pharmacol. Exp. Ther. (1993) 266(3):1620-1625.
55. ITO T, YANO I, TANAKA K, INUI KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J. Pharmacol. Exp. Ther. (1997) 282(2):955-960.
56. ZAMAN GJ, FLENS MJ, VAN LEUSDEN MR et al.: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA (1994) 91(19):8822-8826.
57. KRISHNAMACHARY N, CENTER MS: The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. (1993) 53(16):3658-3661.
58. DOLFINI E, DASDIA T, ARANCIA G et al.: Characterization of a clonal human colon adenocarcinoma line intrinsically resistant to doxorubicin. Br. J. Cancer (1997) 76(1):67-76.
59. CHEN ZS, FURUKAWA T, SUMIZAWA T et al.: ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol. (1999) 55(5):921-928.
60. JEDLITSCHKY G, BURCHELL B, KEPPLER D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. (2000) 275(39):30069-30074.
61. LEIER I, JEDLITSCHKY G, BUCHHOLZ U et al.: The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. (1994) 269(45):27807-27810.
62. STRIDE BD, GRANT CE, LOE DW et al.: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol. Pharmacol. (1997) 52(3):344-353.
63. EVERS R, ZAMAN GJ, VAN DEEMTER L et al.: Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J. Clin. Invest. (1996) 97(5):1211-1218.
64. FLENS MJ, ZAMAN GJ, VAN DER VALK P et al.: Tissue distribution of the multidrug resistance protein. Am. J. Pathol. (1996) 148(4):1237-1247.
65. VAN LUYN MJ, MULLER M, RENES J et al.: Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. Int. J. Cancer (1998) 76(1):55-62.
66. LOE DW, STEWART RK, MASSEY TE, DEELEY RG, COLE SP: ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. (1997) 51(6):1034-1041.
67. BURGER H, FOEKENS JA, LOOK MP et al.: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. (2003) 9(2):827-836.
68. OHISHI Y, ODA Y, UCHIUMI T et al.: ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. (2002) 8(12):3767-3775.
69. PLASSCHAERT SL, VELLENGA E, DE BONT ES et al.: High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk. Lymphoma (2003) 44(1):85-95.
70. PEI QL, KOBAYASHI Y, TANAKA Y et al.: Increased expression of multidrug resistance-associated protein 1 (mrp 1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol. Res. (2002) 22(1):58-64.
71. KAWABE T, CHEN ZS, WADA M et al.: Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. (1999) 456(2):327-331.
72. CUI Y, KONIG J, BUCHHOLZ JK et al.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. (1999) 55(5):929-937.
73. BODO A, BAKOS E, SZERI F, VARADI A, SARKADI B: Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. (2003) 278(26):23529-23537.
74. KEPPLER D, CUI Y, KONIG J, LEIER I, NIES A: Export pumps for anionic conjugates encoded by MRP genes. Adv. Enzyme Regul. (1999) 39:237-246.
75. ISHIKAWA T, ALI-OSMAN F: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. (1993) 268(27):20116-20125.
76. GUTMANN H, FRICKER G, DREWE J, TOEROEK M, MILLER DS: Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol. (1999) 56(2):383-389.
77. MILLER DS: Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J. Pharmacol. Exp. Ther. (2001) 299(2):567-574.
78. VAN AUBEL RA, SMEETS PH, PETERS JG, BINDELS RJ, RUSSEL FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. (2002) 13(3):595-603.
79. NARUHASHI K, TAMAI I, INOUE N et al.: Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob. Agents Chemother. (2002) 46(2):344-349.
80. MOTTINO AD, HOFFMAN T, JENNES L, VORE M: Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. (2000) 293(3):717-723.
81. SCHWAB D, FISCHER H, TABATABAEI A, POLI S, HUWYLER J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. (2003) 46(9):1716-1725.
82. ST-PIERRE MV, SERRANO MA, MACIAS RI et al.: Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(4):R1495-R1503.
83. SUZUKI H, SUGIYAMA Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. (2002) 54(10):1311-1331.
84. HINOSHITA E, UCHIUMI T, TAGUCHI K et al.: Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. (2000) 6(6):2401-2407.
85. NIES AT, KONIG J, PFANNSCHMIDT M et al.: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int. J. Cancer (2001) 94(4):492-499.
86. STEINBACH D, LENGEMANN J, VOIGT A et al.: Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute mycloid leukemia. Clin. Cancer Res. (2003) 9(3):1083-1086.
87. BELINSKY MG, BAIN LJ, BALSARA BB, TESTA JR, KRUH GD: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst. (1998) 90(22):1735-1741.
88. SCHEFFER GL, KOOL M, DE HAAS M et al.: Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. (2002) 82(2):193-201.
89. KOOL M, VAN DER LINDEN M, DE HAAS M et al.: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA (1999) 96(12):6914-6919.
90. LEE K, KLEIN-SZANTO AJ, KRUH GD: Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. (2000) 92(23):1934-1940.
91. MCALEER MA, BREEN MA, WHITE NL, MATTHEWS N: pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem. (1999) 274(33):23541-23548.
92. CHEN ZS, LEE K, KRUH GD: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. (2001) 276(36):33747-33754.
93. NIES AT, SPRING H, THON WF, KFPPLER D, JEDLITSCHKY G: Immunolocalization of multidrug resistance protein 5 in the human genitourinary system. J. Urol. (2002) 167(5):2271-2275.
94. BERA TK, LEE S, SALVATORE G, LEE B, PASTAN I: MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. (2001) 7(8):509-516.
95. TAMMUR J, PRADES C, ARNOULD I et al.: Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene (2001) 273(1):89-96.
96. KOOL M, VAN DER LINDEN M, DE HAAS M, BAAS F, BORST P: Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res. (1999) 59(1):175-182.
97. HOPPER E, BELINSKY MG, ZENG H et al.: Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. (2001) 162(2):181-191.
98. LEGRAND O, SIMONIN G, BEAUCHAMP-NICOUD A, ZITTOUN R, MARIE JP: Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood (1999) 94(3):1046-1056.
99. LITMAN T, BRANGI M, HUDSON E et al.: The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. (2000) 113(Pt 11):2011-2021.
100. DE BRUIN M, MIYAKE K, LITMAN T, ROBEY R, BATES SE: Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett. (1999) 146(2):117-126.
101. ROCCHI E, KHODJAKOV A, VOLK EL et al.: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. (2000) 271(1):42-46.
102. SCHEFFER GL, MALIEPAARD M, PIJNENBORG AC et al.: Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. (2000) 60(10):2589-2593.
103. DIESTRA JE, SCHEFFER GL, CATALA I et al.: Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. (2002) 198(2):213-219.
104. JONKER JW, SMIT JW, BRINKHUIS RF et al.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer. Inst. (2000) 92(20):1651-1656.
105. ELFERINK RO, GROEN AK: Genetic defects in hepatobiliary transport. Biochim. Biophys. Acta. (2002) 1586(2):129-145.
106. FORD JM, HAIT WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. (1990) 42(3):155-199.
107. FORD JM, HAIT WN: Pharmacologic circumvention of multidrug resistance. Cytotechnology (1993) 12(1-3):171-212.
108. KRISHNA R, MAYER LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. (2000) 11(4):265-283.
109. WANG RB, KUO CL, LIEN LL, LIEN EJ: Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. (2003) 28(3):203-228.
110. PIRKER R, FITZGERALD DJ, RASCHACK M et al.: Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res (1989) 49(17):4791-4795.
111. PIRKER R, KEILHAUER G, RASCHACK M, LECHNER C, LUDWIG H: Reversal of multi-drug resistance in human KB cell lines by structural analogs of verapamil. Int. J. Cancer (1990) 45(5):916-919.
112. TWENTYMAN PR: Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporins. Br. J. Cancer (1988) 57(3):254-258.
113. ATADJA P, WATANABE T, XU H, COHEN D: PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev. (1998) 17(2):163-168.
114. NAWRATH H, RASCHACK M: Effects of (-)-desmethoxyverapamil on heart and vascular smooth muscle. J. Pharmacol. Exp. Ther. (1987) 242(3):1090-1097.
115. KRISHNA R, MAYER LD: Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. (1997) 57(23):5246-5253.
116. DI PIETRO A, CONSEIL G, PEREZ-VICTORIA JM et al.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol. Life Sci. (2002) 59(2):307-322.
117. JODOIN J, DEMEULE M, BELIVEAU R: Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta. (2002) 1542(1-3):149-159.
118. CVETKOVIC M, LEAKE B, FROMM MF, WILKINSON GR, KIM RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27(8):866-871.
119. ARCECI RJ: Can multidrug resistance mechanisms be modified? Br. J. Haematol. (2000) 110(2):285-291.
120. MINKO T, KOPECKOVAP, KOPECEK J: Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control Release (1999) 59(2):133-148.
121. TIJERINA M, FOWERS KD, KOPECKOVA P, KOPECEK J: Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials (2000) 21(21):2203-2210.
122. ALAKHOV V, MOSKALEVA E, BATRAKOVA EV, KABANOV AV: Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. (1996) 7(2):209-216.
123. BATRAKOVA EV, LI S, ELMQUIST WF et al.: Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer. (2001) 85(12):1987-1997.
124. MANO Y, SUZUKI H, TERASAKI T et al.: Kinetic analysis of the disposition of MRK16, an anti-P-glycoprotein monoclonal antibody, in tumors: comparison between in vitro and in vivo disposition. J. Pharmacol. Exp. Ther. (1997) 283(1):391-401.
125. NAITO M, TSUGE H, KUROKO C et al.: Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J. Natl. Cancer Inst. (1993) 85(4):311-316.
126. TANG F, BORCHARDT RT: Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE. Pharm. Res. (2002) 19(6):787-793.
127. GUILLEMARD V, URI SARAGOVI H: Prodrug chemotherapeutics bypass P-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene (2004) 23(20):3613-3621.
128. KABANOV AV, BATRAKOVA EV: New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des. (2004) 10(12):1355-1363.
129. GRKOVIC S, BROWN MH, SKURRAY RA: Regulation of bacterial drug export systems. Microbiol. Mol. Biol. Rev. (2002) 66(4):671-701.
130. GRKOVIC S, BROWN MH, SKURRAY RA: Transcriptional regulation of multidrug efflux pumps in bacteria. Semin. Cell Dev. Biol. (2001) 12(3):225-237.
131. HINRICHS W, KISKER C, DUVEL M et al.: Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. Science (1994) 264(5157):418-420.
132. ORTH P, SCHNAPPINGER D, HILLEN W, SAENGER W, HINRICHS W. Structural basis of gene regulation by the tetracycline inducible Tet repressor-operator system. Nat. Struct. Biol. (2000) 7(3):215-219.
133. HELDWEIN EE, BRENNAN RG: Crystal structure of the transcription activator BmrR bound to DNA and a drug. Nature (2001) 409(6818):378-382.
134. SCHUMACHER MA, MILLER MC, GRKOVIC S et al.: Structural mechanisms of QacR induction and multidrug recognition. Science (2001) 294(5549):2158-2163.
135. XU D, YE D, FISHER M, JULIANO RL: Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J. Pharmacol Exp. Ther. (2002) 302(3):963-971.
136. GALSKI H, SULLIVAN M, WILLINGHAM MC et al.: Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol. Cell Biol. (1989) 9(10):4357-4363.
137. HANANIA EG, FU S, ZU Z et al.: Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther. (1995) 2(4):285-294.
138. SORRENTINO BP, BRANDT SJ, BODINE D et al.: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science (1992) 257(5066):99-103.
139. PODDA S, WARD M, HIMELSTEIN A et al.: Transfer and expression of the human multiple drug resistance gene into live mice. Proc. Natl. Acad. Sci. USA (1992) 89(20):9676-9680.
140. BACK DJ, ROGERS SM: Review: first-pass metabolism by the gastrointestinal mucosa. Aliment Pharmacol. Ther. (1987) 1(5):339-357.
141. GOMEZ DY, WACHER VJ, TOMLANOVICH SJ, HEBERT MF, BENET LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. (1995) 58(1):15-19.
142. KOLARS JC, AWNI WM, MERION RM, WATKINS PB: First-pass metabolism of cyclosporin by the gut. Lancet (1991) 338(8781):1488-1490.
143. PAINE MF, SHEN DD, KUNZE KL et al.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. (1996) 60(1):14-24.
144. THUMMEL KE, O'SHEA D, PAINE MF et al.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. (1996) 59(5):491-502.
145. WEBBER IR, PETERS WH, BACK DJ: Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br. J. Clin. Pharmacol. (1992) 33(6):661-664.
146. TENNANT M, MCREE DE: The First structure of a microsomal P450-implications for drug discovery. Curr. Opin. Drug Discov. Devel. (2001) 4(5):671-677.
147. AHMAD N, MUKHTAR H: Cytochrome P450: a target for drug development for skin diseases. J. Invest Dermatol. (2004) 123(3):417-425.
148. GERVASINI G, CARRILLO JA, BENITEZ J: Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds. Clin. Pharmacokinet. (2004) 43(11):693-706.
149. CHRISTIANS U: Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A. Ther. Drug Monit. (2004) 26(2):104-106.
150. AAAS Symposium on the Nature and Functional Role of Cytochrome P450 Mediated Systems. Houston, TX, USA. Drug Metab. Rev. (1979) 10(1):1-87.
151. AHMAD S: The functional roles of cytochrome P450 mediated systems: present knowledge and future areas of investigations. Drug Metab. Rev. (1979) 10(1):1-14.
152. MARSHALL WJ: Enzyme induction by drugs. Its relevance to clinical biochemistry. Ann. Clin. Biochem. (1978) 15(1):55-64.
153. CARRIERE V, CHAMBAZ J, ROUSSET M: Intestinal responses to xenobiotics. Toxicol. In Vitro (2001) 15(4-5):373-378.
154. GUENGERICH FP: Uncommon P450-catalyzed reactions. Curr. Drug Metab. (2001) 2(2):93-115.
155. SCHUETZ EG: Induction of cytochromes P450. Curr. Drug Metab. (2001) 2(2):139-147.
156. ANZENBACHER P, ANZENBACHEROVA E: Cytochromes P450 and metabolism of xenobiotics. Cell Mol. Life Sci. (2001) 58(5-6):737-747.
157. POL S, LEBRAY P: N-acetylcysteine for paracetamol poisoning: effect on prothrombin. Lancet (2002) 360(9340):1115.
158. BROSEN K: Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin. Pharmacokinet. (1990) 18(3):220-239.
159. INGELMAN-SUNDBERG M: Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369(1):89-104.
160. KELLY SL, LAMB DC, JACKSON CJ, WARRILOW AG, KELLY DE: The biodiversity of microbial cytochromes P450. Adv. Microb. Physiol. (2003) 47:131-186.
161. NEBERT DW, ADESNIK M, COON MJ et al.: The P450 gene superfamily: recommended nomenclature. DNA (1987) 6(1):1-11.
162. SLAUGHTER RL, EDWARDS DJ: Recent advances: the cytochrome P450 enzymes. Ann. Pharmacother. (1995) 29(6):619-624.
163. DU L, HOFFMAN SM, KEENEY DS: Epidermal CYP2 family cytochromes P450. Toxicol. Appl. Pharmacol. (2004) 195(3):278-287.
164. DING X, KAMINSKY LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Ann. Rev. Pharmacol. Toxicol. (2003) 43:149-173.
165. LIU M, HURN PD, ALKAYED NJ: Cytochrome P450 in neurological disease. Curr. Drug Metab. (2004) 5(3):225-234.
166. ZHAO X, IMIG JD: Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr. Drug Metab. (2003) 4(1):73-84.
167. WATKINS PB, WRIGHTON SA, SCHUETZ EG, MOLOWA DT, GUZELIAN PS: Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. (1987) 80(4):1029-1036.
168. SHEN DD, KUNZE KL, THUMMEL KF: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. (1997) 27(2-3):99-127.
169. KOLARS JC, SCHMIEDLIN-REN P, SCHUETZ JD, FANG C, WATKINS PB: Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. (1992) 90(5):1871-1878.
170. PARKINSON A: An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol. Pathol. (1996) 24(1):48-57.
171. GUENGERICH FP, MARTIN MV, BEAUNE PH et al.: Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. (1986) 261(11):5051-5060.
172. LOWN KS, KOLARS JC, THUMMEL KE et al.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. (1994) 22(6):947-955.
173. DING R, TAYROUZ Y, RIEDEL KD et al.: Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. (2004) 76(1):73-84.
174. SAGIR A, SCHMITT M, DILGER K, HAUSSINGER D: Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion (2003) 68(1):41-48.
175. JIN L, CHEN IW, CHIBA M, LIN JH: Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. Xenobiotica (2003) 33(6):643-654.
176. PFISTER M, LABBE L, LU JF et al.: Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin. Pharmacol. Ther. (2002) 72(2):133-141.
177. MALATY LI, KUPER JJ: Drug interactions of HIV protease inhibitors. Drug Saf. (1999) 20(2):147-169.
178. ERESHEFSKY L, RIESENMAN C, LAM YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin. Pharmacokinet. (1995) 29(Suppl.1):10-18.
179. HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. (2000) 85(1):11-28.
180. VON MOLTKE LL, GREENBLATT DJ, SCHMIDER J, HARMATZ JS, SHADER RI: Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. (1995) 29(Suppl.1):33-43.
181. VON MOLTKE LL, GREENBLATT DJ, SCHMIDER J et al.: Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J. Clin. Pharmacol. (1996) 36(9):783-791.
182. GREGOR KJ, WAY K, YOUNG CH, JAMES SP: Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen? J. Affect. Disord. (1997) 46(1):59-67.
183. OZMINKOWSKI RJ, HYLAN TR, MELFI CA et al.: Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P450 system. Clin. Ther. (1998) 20(4):780-796.
184. VELLA S, FLORIDIA M: Saquinavir. Clinical pharmacology and efficacy. Clin. Pharmacokinet. (1998) 34(3):189-201.
185. HSU A, GRANNEMAN GR, BERTZ RJ: Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. (1998) 35(4):275-291.
186. WILLIAMS GC, SINKO PJ: Oral absorption of the HIV protease inhibitors: a current update. Adv. Drug Deliv. Rev. (1999) 39(1-3):211-238.
187. LI X, CHAN WK: Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Deliv. Rev. (1999) 39(1-3):81-103.
188. BLACK DJ, KUNZE KL, WIENKERS LC et al.: Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab. Dispos. (1996) 24(4):422-428.
189. KUNZE KL, WIENKERS LC, THUMMEL KE, TRAGER WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. (1996) 24(4):414-421.
190. HARDER S, THURMANN P: Clinically important drug interactions with anticoagulants. An update. Clin. Pharmacokinet. (1996) 30(6):416-444.
191. ZHOU S, CHAN E, PAN SQ, HUANG M, LEE EJ: Pharmacokinetic interactions of drugs with St John's s wort. J. Psychopharmacol. (2004) 18(2):262-276.
192. OUELLET D, HSU A, QIAN J et al.: Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. (1998) 46(2):111-116.
193. MOYLE GJ, BACK D: Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. (2001) 2(2):105-113.
194. QAZI NA, MORLESE JF, POZNIAK AL: Lopinavir/ritonavir (ABT-378/r). Expert Opin. Pharmacother. (2002) 3(3):315-327.
195. MOYLE G: Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. AIDS Patient Care STDS (2002) 16(12):585-597.
196. BERGSHOEFF AS, WOLFS TF, GEELEN SP, BURGER DM: Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use. Ann. Pharmacother. (2003) 37(4):521-525.
197. JOHNSON M, PETERS B: Saquinavir/low-dose ritonavir: its use in HIV infection. AIDS Rev. (2003) 5(1):44-51.
198. LOUTFY M, RABOUD J, THOMPSON C et al. Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin. Trials (2003) 4(5):301-310.
199. ARORA V, CATE ML, CHOSH C, IVERSEN PL: Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab. Dispos. (2002) 30(7):757-762.
200. JOVER R, BORT R, GOMEZ-LECHON MJ, CASTELL JV: Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology (2001) 33(3):668-675.
201. ARORA V, KNAPP DC, REDDY MT, WELLER DD, IVERSEN PL: Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P450 3A2 following oral administration in rats. J. Pharm. Sci. (2002) 91(4):1009-1018.
202. ARORA V, HANNAH TL, IVERSEN PL, BRAND RM: Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm. Res. (2002) 19(10):1465-1470.
203. ARORA V, IVERSEN PL: Redirection of drug metabolism using antisense technology. Curr. Opin. Mol. Ther. (2001) 3(3):249-257.
204. KATOH M, NAKAJIMA M, YAMAZAKI H, YOKOI T. Inhibitory effects of CYP3A4 substrates and their metabolites on P- glycoprotein-mediated transport. Eur. J. Pharm. Sci. (2001) 12(4):505-513.
205. KOLARS JC, STETSON PL, RUSH BD et al.: Cyclosporine metabolism by P450IIIA in rat enterocytes-another determinant of oral bioavailability? Transplantation (1992) 53(3):596-602.
206. CHIOU WL, CHUNG SM, WU TC: Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm. Res. (2000) 17(8):903-905.
207. WACHER VJ, SALPHATI L, BENET LZ: Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. (2001) 46(1-3):89-102.
208. WATKINS PB: The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug. Deliv. Rev. (1997) 27(2-3):161-170.
209. MITRA AK, PATEL J: Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics (2001) 2(4):401-415.
210. MEYER UA: Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet (2004) 5(9):669-676.
211. ANGLICHEAU D, LEGENDRE C, THERVET E: Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation (2004) 78(3):311-315.
212. SENN S: Individual response to treatment: is it a valid assumption? BMJ (2004) 329(7472):966-968.
213. ISHIKAWA T, HIRANO H, ONISHI Y, SAKURAI A, TARUI S: Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. (2004) 19(1):1-14.
214. MEALEY KL: Therapeutic implications of the MDR-1 gene. J. Vet. Pharmacol. Ther. (2004) 27(5):257-264.
215. ISHIKAWA T, ONISHI Y, HIRANO H et al.: Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biol. Pharm. Bull (2004) 27(7):939-948.
216. EICHELBAUM M, FROMM MF, SCHWAB M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. (2004) 26(2):180-185.
217. IEIRI I, TAKANE H, OTSUBO K: The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. (2004) 43(9):553-576.
218. JAMROZIAK K, ROBAK T: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology (2004) 9(2):91-105.
219. LIN JH, LU AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Ann. Rev. Pharmacol. Toxicol. (2001) 41:535-567.
220. GARCIA-MARTIN E, MARTINEZ C, PIZARRO RM et al.: CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther. (2002) 71(3):196-204.
221. CHANG GWM, KAM PC: The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia (1999) 54(1):42-50.
222. SYNOLD TW, DUSSAULT I, FORMAN BM: The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. (2001) 7(5):584-590.
223. GEICK A, EICHELBAUM M, BURK O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. (2001) 276(18):14581-14587.
224. QUATTROCHI LC, GUZELIAN PS: Cyp3A regulation: from pharmacology to nuclear receptors. Drug Metab. Dispos. (2001) 29(5):615-622.
225. JONES SA, MOORE LB, SHENK JL et al.: The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. (2000) 14(1):27-39.
226. MASUYAMA H, HIRAMATSU Y, MIZUTANI Y, INOSHITA H, KUDO T: The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol. Cell Endocrinol. (2001) 172(1-2):47-56.
227. CATANIA VA, SANCHEZ POZZI EJ, LUQUITA MG et al.: Co-regulation of expression of Phase II metabolizing enzymes and multidrug resistance-associated protein 2. Ann. Hepatol. (2004) 3 (1):11-17.
228. DICKINS M: Induction of cytochromes P450. Curr Top Med. Chem. (2004) 4(16):1745-1766.
229. ELORANTA JJ, KULLAK-UBLICK GA: Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch. Biochem. Biophys. (2005) 433(2):397-412.
230. GOODWIN B, MOORE JT: CAR: detailing new models. Trends Pharmacol. Sci. (2004) 25(8):437-441.
231. HANDSCHIN C, MEYER UA: Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. (2003) 55(4):649-673.
232. HANDSCHIN C, MEYER UA: Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch. Biochem. Biophys. (2005) 433(2):387-396.
233. KULLAK-UBLICK GA, BECKER MB: Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. (2003) 35(4):305-317.
234. MANNEL M: Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf. (2004) 27(11):773-797.
235. MOHAN R, HEYMAN RA: Orphan nuclear receptor modulators. Curr. Top Med. Chem. (2003) 3(14):1637-1647.
236. MULLER M: Transcriptional control of hepatocanalicular transporter gene expression. Semin. Liver Dis. (2000) 20(3):323-337.
237. TRABER MG: Vitamin E, nuclear receptors and xenobiotic metabolism. Arch. Biochem. Biophys. (2004) 423(1):6-11.
238. WANG H, LECLUYSE EL: Role of Orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. (2003) 42(15):1331-1357.
239. YOU L: Steroid hormone biotransformation and xenobiotic induction of hepatic steroid metabolizing enzymes. Chem. Biol. Interact. (2004) 147(3):233-246.
240. TANG-WAI DF, BROSSI A, ARNOLD LD, GROS P: The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistance. Biochemistry (1993) 32(25):6470-6476.
241. RICE A, MICHAELIS ML, GEORG G et al.: Overcoming the blood-brain barrier to taxane delivery for neurodegenerative diseases and brain tumors. J. Mol. Neurosci. (2003) 20(3):339-343.
242. WENDER PA, HEGDE SG, HUBBARD RD, ZHANG L, MOOBERRY SL: Synthesis and biological evaluation of (-)-laulimalide analogues. Org. Lett. (2003) 5(19):3507-3509.